RWJ 416457 | CAS#474016-05-2 | oxazolidinone

MedKoo Cat#: 461584 | Name: RWJ 416457

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RWJ 416457 is a pyrrolopyrazolyl-substituted oxazolidinone with activity against antibiotic-susceptible and -resistant gram-positive pathogens.

Chemical Structure

RWJ 416457

CAS#474016-05-2

Theoretical Analysis

MedKoo Cat#: 461584

Name: RWJ 416457

CAS#: 474016-05-2

Chemical Formula: C18H20FN5O3

Exact Mass: 373.1550

Molecular Weight: 373.38

Elemental Analysis: C, 57.90; H, 5.40; F, 5.09; N, 18.76; O, 12.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RWJ 416457; RWJ-416457; RWJ416457;

IUPAC/Chemical Name

(S)-N-((3-(3-fluoro-4-(2-methyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide

InChi Key

UCBHICFFJKDMMR-AWEZNQCLSA-N

InChi Code

InChI=1S/C18H20FN5O3/c1-11(25)20-6-14-9-24(18(26)27-14)13-3-4-17(15(19)5-13)23-8-12-7-22(2)21-16(12)10-23/h3-5,7,14H,6,8-10H2,1-2H3,(H,20,25)/t14-/m0/s1

SMILES Code

CC(NC[C@H]1CN(C2=CC=C(N3CC4=NN(C)C=C4C3)C(F)=C2)C(O1)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 373.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Santoro CM, Bush K, Abbanat D. Characterisation of Staphylococcus aureus and Enterococcus faecalis mutants with reduced susceptibility to the investigational oxazolidinone RWJ-416457. Int J Antimicrob Agents. 2010 Nov;36(5):424-9. doi: 10.1016/j.ijantimicag.2010.07.007. Epub 2010 Sep 17. PubMed PMID: 20846828. 2: Hilliard JJ, Fernandez J, Melton J, Macielag MJ, Goldschmidt R, Bush K, Abbanat D. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob Agents Chemother. 2009 May;53(5):2028-33. doi: 10.1128/AAC.00833-08. Epub 2009 Mar 9. PubMed PMID: 19273686; PubMed Central PMCID: PMC2681548. 3: Cheung EY, Peterson ML, Chiarella R, Foxman BM. A novel oxazolidinone antibiotic: RWJ-416457. Acta Crystallogr C. 2010 May;66(Pt 5):o249-51. doi: 10.1107/S0108270110009339. Epub 2010 Apr 13. PubMed PMID: 20442508. 4: Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan. PubMed PMID: 26503656; PubMed Central PMCID: PMC4704221. 5: Foleno BD, Abbanat D, Goldschmidt RM, Flamm RK, Paget SD, Webb GC, Wira E, Macielag MJ, Bush K. In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob Agents Chemother. 2007 Jan;51(1):361-5. Epub 2006 Nov 13. PubMed PMID: 17101672; PubMed Central PMCID: PMC1797661. 6: Livermore DM, Warner M, Mushtaq S, North S, Woodford N. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci. Antimicrob Agents Chemother. 2007 Mar;51(3):1112-4. Epub 2007 Jan 8. PubMed PMID: 17210773; PubMed Central PMCID: PMC1803128. 7: Schmidt S, Sabarinath SN, Barbour A, Abbanat D, Manitpisitkul P, Sha S, Derendorf H. Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009 Dec;53(12):5039-45. doi: 10.1128/AAC.00633-09. Epub 2009 Sep 28. PubMed PMID: 19786607; PubMed Central PMCID: PMC2786350. 8: Dong J, Karki SB, Parikh M, Riggs JC, Huang L. Oxidative degradation studies of an oxazolidinone-derived antibacterial agent, RWJ416457, in aqueous solutions. Drug Dev Ind Pharm. 2012 Nov;38(11):1289-97. Epub 2012 Jan 23. PubMed PMID: 22263626.